MARKET

SLDB

SLDB

SOLID BIOSCIENCE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.940
-0.090
-2.23%
Closed 18:41 06/16 EDT
OPEN
3.980
PREV CLOSE
4.030
HIGH
4.030
LOW
3.850
VOLUME
791.21K
TURNOVER
--
52 WEEK HIGH
11.58
52 WEEK LOW
1.930
MARKET CAP
434.57M
P/E (TTM)
-2.8943
1D
5D
1M
3M
1Y
5Y
Thinking about buying stock in Aethlon Medical, Checkpoint Therapeutics, ContextLogic, Clean Energy Fuels, or Solid Biosciences?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, CKPT, WISH, CLNE, and SLDB.
PR Newswire - PRF · 06/09 12:30
WKHS, CLNE, GEO and CLOV among premarket gainers
Aethlon Medical (AEMD) +280% after publication of its case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier®.Checkpoint Therapeutics (CKPT) +50%.Antelope Enterprise Holdings Limited (AEHL) +45%.SPI Energy (SPI) +41% as
Seekingalpha · 06/09 12:28
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) rose 72.4% to $3.81 in pre-market trading following Zacks article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An Infected Patient.'
Benzinga · 06/09 11:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 06/08 12:07
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers
Benzinga · 06/07 21:49
Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer, effective June 1...
GlobeNewswire · 06/07 11:49
Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Regulatory Officer, Dr. Iman ...
GlobeNewswire · 06/07 11:49
BRIEF-Solid Biosciences Announces Appointment Of Iman Barilero, Pharmd, Ph.D., As Chief Regulatory Officer
reuters.com · 06/07 11:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLDB. Analyze the recent business situations of SOLID BIOSCIENCE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLDB stock price target is 9.67 with a high estimate of 20.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 144
Institutional Holdings: 82.31M
% Owned: 74.63%
Shares Outstanding: 110.30M
TypeInstitutionsShares
Increased
32
15.50M
New
40
11.86M
Decreased
21
2.20M
Sold Out
11
634.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.64%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Chairman/Director
Ian Smith
President/Chief Executive Officer/Co-Founder/Director
Ilan Ganot
Chief Financial Officer/Treasurer
Stephen DiPalma
Chief Operating Officer
Joel Schneider
Chief Scientific Officer
Carl Morris
Other
Iman Barilero
Secretary
Erin Brennan
Lead Director/Independent Director
Adam Stone
Director
Clare Kahn
Independent Director
Matthew Arnold
Independent Director
Martin Freed
Independent Director
Robert Huffines
Independent Director
Georgia Keresty
Independent Director
Adam Koppel
Independent Director
Sukumar Nagendran
Independent Director
Rajeev Shah
Independent Director
Lynne Sullivan
No Data
  • All
  • Financials
  • Insiders
More
About SLDB
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

Webull offers kinds of Solid Biosciences Inc stock information, including NASDAQ:SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.